Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

被引：27

作者：

Cortes, Jorge E.

Tallman, Martin S.

Schiller, Gary

Trone, Denise

Gammon, Guy

Goldberg, Stuart

Perl, Alexander E.

Marie, Jean Pierre

Martinelli, Giovanni

Levis, Mark

机构：

来源：

BLOOD | 2013年 / 122卷 / 21期

关键词：

D O I：

10.1182/blood.V122.21.494.494

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

494

引用

页数：2

共 50 条

[21] Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation [J].

Sandmaier, Brenda M. ;

Khaled, Samer K. ;

Oran, Betul ;

Gammon, Guy ;

Trone, Denise ;

Frankfurt, Olga .

BLOOD, 2014, 124 (21)

[22] Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial (vol 20, pg 986, 2019) [J].

Cortes, J. E. ;

Khaled, S. ;

Martinelli, G. .

LANCET ONCOLOGY, 2019, 20 (07) :E346-E346

[23] Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study [J].

Yu, Sijian ;

Zhang, Yu ;

Yu, Guopan ;

Wang, Yu ;

Shao, Ruoyang ;

Du, Xin ;

Xu, Na ;

Lin, Dongjun ;

Zhao, Weihua ;

Zhang, Xiong ;

Xiao, Jie ;

Sun, Zhiqiang ;

Deng, Lan ;

Liang, Xinquan ;

Zhang, Hongyu ;

Guo, Ziwen ;

Dai, Min ;

Shi, Pengcheng ;

Huang, Fen ;

Fan, Zhiping ;

Liu, Qiong ;

Lin, Ren ;

Jiang, Xuejie ;

Xuan, Li ;

Liu, Qifa ;

Jin, Hua .

JOURNAL OF INTERNAL MEDICINE, 2024, 295 (02) :216-228

[24] Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study [J].

Yu, Sijian ;

Liu, Qifa ;

Zhang, Yu ;

Yu, Guopan ;

Wang, Yu ;

Shao, Ruoyang ;

Liu, Qiong .

BLOOD, 2023, 142

[25] Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial [J].

Cortes, Jorge ;

Perl, Alexander E. ;

Dohner, Hartmut ;

Kantarjian, Hagop ;

Martinelli, Giovanni ;

Kovacsovics, Tibor ;

Rousselot, Philippe ;

Steffen, Bjorn ;

Dombret, Herve ;

Estey, Elihu ;

Strickland, Stephen ;

Altman, Jessica K. ;

Baldus, Claudia D. ;

Burnett, Alan ;

Kramer, Alwin ;

Russell, Nigel ;

Shah, Neil P. ;

Smith, Catherine C. ;

Wang, Eunice S. ;

Ifrah, Norbert ;

Gammon, Guy ;

Trone, Denise ;

Lazzaretto, Deborah ;

Levis, Mark .

LANCET ONCOLOGY, 2018, 19 (07) :889-903

[26] Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML) [J].

Perl, Alexander E. ;

Cortes, Jorge E. ;

Ganguly, Siddhartha ;

Khaled, Samer K. ;

Kraemer, Alwin ;

Martinelli, Giovanni ;

Russell, Nigel H. ;

Chang, Ken C. ;

Kato, Kazunobu ;

Yan, Yuhu ;

Xu, Li-An ;

Korkhov, Sergey ;

Gunnel, Tobias ;

Sumi, Hiroyuki ;

Lesegretain, Arnaud ;

Berisha, Flora ;

Mires, Derek ;

Benzohra, Aziz ;

Isoyama, Takeshi ;

Dos Santos, Cedric ;

Levis, Mark J. .

CANCER RESEARCH, 2020, 80 (16)

[27] Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) [J].

Perl, Alexander E. ;

Cortes, Jorge E. ;

Ganguly, Siddhartha ;

Khaled, Samer K. ;

Kramer, Alwin ;

Martinelli, Giovanni ;

Russell, Nigel H. ;

Chang, Ken C. N. ;

Mires, Derek E. ;

Kato, Kazunobu ;

Zhang, Yufen ;

Korkhov, Sergey ;

Wang, Zhenyu ;

Gunnel, Tobias ;

Sumi, Hiroyuki ;

Isoyama, Takeshi ;

Lesegretain, Arnaud ;

Berisha, Flora ;

Dos Santos, Cedric E. ;

Levis, Mark J. .

BLOOD, 2019, 134

[28] Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia [J].

Wang, Jianxiang ;

Jiang, Bin ;

Li, Jian ;

Liu, Ligen ;

Du, Xin ;

Jiang, Hao ;

Hu, Jianda ;

Yuan, Menghe ;

Sakatani, Taishi ;

Kadokura, Takeshi ;

Takeuchi, Masato ;

Izuka, Shunsuke ;

Girshova, Larisa ;

Tan, Jerome ;

Bondarenko, Sergey N. ;

Wong, Lily L. L. ;

Khuhapinant, Archrob ;

Martynova, Elena ;

Hasabou, Nahla ;

Tiu, Ramon V. .

BLOOD, 2021, 138

[29] RESULTS OF A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF LENALIDOMIDE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) [J].

O'Brien, Maureen ;

Alonzo, Todd ;

Cooper, Todd ;

Levine, John ;

Brown, Patrick ;

Slone, Tamra ;

Benettaib, Bouchra ;

Biserna, Noha ;

Poon, Jennifer ;

Quan, Jackie ;

Simcock, Mathew ;

Weiss, Daniel ;

Zimmerman, Linda ;

Kolb, Edward .

PEDIATRIC BLOOD & CANCER, 2018, 65

[30] A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML) [J].

Zwaan, C. Michel ;

Kolb, Edward Anders ;

Mires, Derek E. ;

Vigliotti, Michele ;

Xie, Jingdong ;

Downs, Pamela ;

DeCillis, Arthur P. ;

Rabik, Cara A. ;

Cooper, Todd M. .

BLOOD, 2019, 134

← 1 2 3 4 5 →